Up And Down The Ladder… Job Changes
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone?
And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Curis hired Ali Fattaey as president and chief operating officer. Previous...
Source: Pharmalot - February 22, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized AcelRx Ariad Pharmaceuticals BioFocus Chimerix Curis Greenphire Gyros Lundbeck Protein Science Symphony Clinical Research Source Type: blogs
Through the looking glass: The costs of care
There is a blizzard of questions flying in any health care transaction. From “How are you feeling?” to “Is this a side effect?” to “When would you like to schedule your appointment?” – questions aren’t in short supply. In my last post, I asked the big question that isn’t on the lips of many patients: “How much is that?”
Now it seems that question is on more lips. In the three months since I first asked it here, a number of stories have emerged that show consumers are more interested in cost details than they have been before. Getting that question answered, however, is still a big challenge.
Just las...
Source: Disruptive Women in Health Care - February 19, 2013 Category: Health Medicine and Bioethics Commentators Authors: dw at disruptivewomen.net Tags: Cost Source Type: blogs
2012: Banner Year for New Drugs
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
As part of the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) promotes and protects the health of Americans by assuring that all prescription and over-the-counter drugs are safe and effective. The CDE...
Source: Highlight HEALTH - February 13, 2013 Category: Medical Scientists Authors: Walter Jessen, Ph.D. Source Type: blogs
Best Post of August 2012: A case of renal cell carcinoma metastatic to a meningioma
The next in our "Best of the Month" series is from August 9, 2012:A 74-year-old woman with a history of a seizure disorder had been followed for several years with a stable and unsymptomatic left parasagittal dural-based brain tumor presumed to be a benign meningioma. Recently, though, the lesion increased in size and hemorrhaged, leaving her significantly paretic on the right side. Neurosurgery thereupon performed a craniotomy for tumor removal. Intraoperative frozen section diagnosis was meningioma. But, upon receipt of the permanent sections, I was impressed by the staghorn vessels at low power and hemangioperic...
Source: neuropathology blog - January 25, 2013 Category: Pathologists Tags: neoplasms Best of the Month series Source Type: blogs
Scary monsters...maybe
When I was a small boy I believed in monsters, since I grew up during the beginning of the Cold War, when every Saturday you could drop a quarter to watch a creature triple feature at the local theater. I also suffered serious abuse throughout most of my youth. To this day, nearing my 7th decade on this God forsaken rock, I still suffer from severe sleep disorders. My p\arents grew very frustrated with all my phobias, "how many times do we have to tall you there are NO monsters. Now go to bed and turn off the light." Decades later I learned my parents lied, there are monsters, not from outer space or mutated lizards, but g...
Source: Nightmare Hall - Welcome to my nightmare - January 20, 2013 Category: HIV AIDS Source Type: blogs
---
ImmunohistochemistryImmunohistochemistry in the differential diagnosis ofclear cell carcinomas from the kidney, liver, and lung Clear cell carcinoma is a common specimen seen by many surgical pathologists. Given an appropriate clinical context (for example, a patient with a large kidney mass), determining the nature and origin of a clear cell carcinoma can be very easy. However, in other situations this can be a challenging task, primarily because of the tremendous degree of overlap in the morphologic appearance of clear cell carcinomas from different primary sites. This month, we discuss the utility of a number ...
Source: Oncopathology - April 2, 2012 Category: Cancer & Oncology Source Type: blogs
